Literature DB >> 8786531

Persistent activation of the dopamine D1 receptor contributes to prolonged receptor desensitization: studies with A-77636.

C W Lin1, B R Bianchi, T R Miller, M A Stashko, S S Wang, P Curzon, L Bednarz, K E Asin, D R Britton.   

Abstract

A-77636 is a dopamine (DA) D1 receptor-selective agonist that was previously shown to elicit beneficial responses in animal models of Parkinson's disease (PD) (Kebabian et al.: Eur. J. Pharmacol. 229: 203, 1992). However, A-77636 is of limited potential for PD therapy because it induces rapid tolerance in vivo. To understand the basis of rapid onset of tolerance to the compound, we conducted studies to compare the in vitro properties of A-77636 and A-81686; the latter is a structurally related D1 agonist that did not induce significant tolerance in vivo under similar experimental conditions. With SK-N-MC, a neuroblastoma cell line, as an in vitro model for the D1 receptor, significant differences in D1 receptor function were noted after pretreatment with the two compounds. Specifically, 1-hr pretreatment with A-77636 resulted in significant residual cAMP production, even after the drug solution was removed and the cells were washed. The residual cAMP activity was selectively inhibited by SCH 23390, a selective D1 antagonist. The residual cAMP activity declined with pretreatment time, and after 4-hr pretreatment, little residual cAMP production was observed. Cotreatment of SK-N-MC cells with SCH 23390 and A-77636 did not prevent residual cAMP production by A-77636. In contrast, A-81686 did not elicit residual cAMP production is SK-N-MC cells. Although A-77636 treated cells were devoid of agonist response 4 hr after drug removal, A-81686-treated cells exhibited significant cAMP response after drug removal. Preincubation of rat striatal membranes with A-77636 resulted in a large decrease in D1 receptor binding, despite repeated washings, whereas A-81686 pretreatment caused only a small reduction in D1 receptor binding. On the basis of the present data, we conclude that A-77636 dissociates slowly from the D1 receptor. The continued activation of the D1 receptor by A-77636 leads to inability of the receptor to recover its responsivity, which may explain its long duration of action and its ability to induce rapid behavioral tolerance in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8786531

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

Review 1.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

2.  Functional selectivity of dopamine D1 receptor agonists in regulating the fate of internalized receptors.

Authors:  Jessica P Ryman-Rasmussen; Adam Griffith; Scott Oloff; Nagarajan Vaidehi; Justin T Brown; William A Goddard; Richard B Mailman
Journal:  Neuropharmacology       Date:  2006-10-24       Impact factor: 5.250

Review 3.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 4.  The lipophilic bullet hits the targets: medicinal chemistry of adamantane derivatives.

Authors:  Lukas Wanka; Khalid Iqbal; Peter R Schreiner
Journal:  Chem Rev       Date:  2013-02-25       Impact factor: 60.622

5.  Differential ability of D1 and D2 dopamine receptor agonists to induce and modulate expression and reinstatement of cocaine place preference in rats.

Authors:  Danielle L Graham; Regis Hoppenot; April Hendryx; David W Self
Journal:  Psychopharmacology (Berl)       Date:  2006-07-12       Impact factor: 4.530

6.  Relationship between development of cross-sensitization to MK-801 and delayed increases in glutamate levels in the nucleus accumbens induced by a high dose of methamphetamine.

Authors:  K Ito; T Abekawa; T Koyama
Journal:  Psychopharmacology (Berl)       Date:  2006-06-01       Impact factor: 4.530

7.  Morphine responsiveness to thermal pain stimuli is aging-associated and mediated by dopamine D1 and D3 receptor interactions.

Authors:  Sophia Samir; Alexander P Yllanes; Perrine Lallemand; Kori L Brewer; Stefan Clemens
Journal:  Neuroscience       Date:  2017-02-28       Impact factor: 3.590

8.  Comparison of the D₁ dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease.

Authors:  John D McCorvy; Val J Watts; David E Nichols
Journal:  Psychopharmacology (Berl)       Date:  2012-01-06       Impact factor: 4.530

9.  Tolerance to the procholinergic action of the D1 receptor full agonist dihydrexidine.

Authors:  Mark R Wade; George G Nomikos
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

Review 10.  Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

Authors:  Amy F T Arnsten; Ragy R Girgis; David L Gray; Richard B Mailman
Journal:  Biol Psychiatry       Date:  2016-01-18       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.